1. Scrip
  3. >>South Korea

Korean Firms Readying To Compete In Global GLP-1 Obesity Space

Hanmi Leading With Phase III Trial

 
• By Jung Won Shin

With Hanmi's progress in changing the main indication of its GLP-1 contender efpeglenatide to obesity, Scrip takes an infographic look at what other Korean firms are doing in both this indication and elsewhere in the GLP-1 space. 

obesity drugs
Several Korean Firms Vying In GLP-1 Drug Race • Source: Shutterstock

With the Phase III SELECT trial for Novo Nordisk A/S’s Wegovy (semaglutide) showing a statistically significant reduction in major adverse cardiovascular events, the spotlight is shining anew on GLP-1 agonist-based obesity treatments and also on other companies developing drugs in this class.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By Jung Won Shin

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By Jung Won Shin

South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.

More from Focus On Asia

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By Lisa Takagi

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

AstraZeneca Logs Japan Growth Despite Price Cuts

 
• By Lisa Takagi

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.